USA Pediatric Proton Therapy Market, Patient Numbers, Forecast By Age & Tumors (36 Cancer Types Analyzed)

    USA Pediatric Proton Therapy Market, Patient Numbers, Forecast By Age & Tumors (36 Cancer Types Analyzed)
    Date: 27 Jul, 2017              Type: Medical Devices              Pages: 195

    • Electronic Access - Single User License
      $1,700.00
    • CD-ROM Mail Delivery
      $1,800.00
    • Hard-copy Mail Delivery
      $1,900.00
    • Electronic Access - Multi User License
      $2,500.00

    Get 10% Free Customization in this Report

    USA Pediatric Proton Therapy Market has potential to reach close to US$ 350 Million by the end of year 2021. But its actual market is predicted to be less than even half of this figure. The difference between this actual and potential market is due to its demand and supply gap. In United States, the cancer incidence among pediatric is rising at rapid pace. USA has largest and more efficient proton therapy center in world due to long history of its proton therapy research and huge investment on center development.


    Age Group of (1-4) has the Largest Cancer Evidence in USA Pediatric Proton Therapy Market

    In this report United States pediatric proton therapy market is divided into five age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year. Out of these age groups (1-4) age group has largest market. 


    Ependymoma Cancerous Tumor has the Highest Market among 36 Types of Cancer which has been studied in the report

    The largest treated pediatric patient with proton therapy in USA is Ependymoma which has almost 15 percent share in United States pediatric proton therapy market. Moreover the ability of proton therapy to treat numerous types of pediatric cancer in a more efficient way than traditional radiotherapy has made it preferential choice for pediatric cancer patients.


    Increasing Cancer Incidence Among Pediatric and Phenomenal Progress in Technological Development of Proton Therapy Across the Period of Time has made it Key driver for Rapid Growth in United States

    Proton Therapy has gained prominence in such a short period due to continuous development of cutting-edge technology like intensity-modulated proton therapy (IMPT) and pencil beam technology. Moreover rising cancer incidence among children in United States reinforced pediatric proton therapy market for faster growth.


    USA Pediatric Proton Therapy Market, Patient Numbers, Forecast By Age & Tumors (36 Cancer Types Analyzed) is the 16th report published by Renub Research on Proton Therapy Market. This 195 page report with 182 figures and 3 Tables provides: Pediatric Proton Therapy Market, Proton Therapy Patient Numbers (both by Age Group and Type of Tumors) Technology being used at these Proton Therapy Centers. The report also studies the Proton Therapy Sales & Forecast of four companies IBA, Varian Medical Systems, Mitsubishi and Hitachi. 


    Type of Tumors Market & Patient Numbers Studied in the Report

    1.    Glioma, Low Grade
    2.    Glioma, High Grade
    3.    Medulloblastoma
    4.    Ependymoma
    5.    ATRT
    6.    Germinoma, Pure
    7.    Germ Cell Tumor
    8.    Craniopharyngioma
    9.    PNET
    10.    Pineoblastoma
    11.    Chordoma/Chondrosarcoma
    12.    Meningioma
    13.    AVM
    14.    Adenoma
    15.    Choroid Plexus Carcinoma
    16.    Retinoblastoma
    17.    Osteosarcoma
    18.    Ewing Sarcoma
    19.    Rhabdomyosarcoma
    20.    Other Sarcoma, High Grade
    21.    Other Sarcoma, Low Grade
    22.    Teratoma
    23.    Neuroblastoma
    24.    Ganglioglioma
    25.    Wilm’s Tumor
    26.    Carcinoma (non-CPC)
    27.    Lymphoma, Hodgkin’s
    28.    Lymphoma, Non-hodgkin’s
    29.    Leukemia
    30.    Desmoid
    31.    Melanoma
    32.    Pineal Parenchymal Tumor
    33.    Esthesioneuroblastoma
    34.    Angiofibroma
    35.    Extrarenal Rhabdoid Tumor
    36.    Others


    Age Group Studied in Report
     
    1.    Age Group (<1) Year
    2.    Age Group (1-4) Year    
    3.    Age Group (5-9) Year    
    4.    Age Group (10-14) Year
    5.    Age Group (15-18) Year

     

    Key Companies Proton Therapy Sales & Forecast (2010 – 2021) Covered in this report

    1.    IBA 
    2.    Varian Medical Systems
    3.    Mitsubishi 
    4.    Hitachi  

     

    Key Questions Answered in the Report?   

    •    What is the Pediatric Proton Therapy Market in United States and its growth potential in Future?
        How Many Pediatric Patients are treated by Proton Beam Therapy in United States?
    •    What is the Pediatric Proton Therapy Market by Age Group age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year in United States and its Forecast?
    •    How Many Pediatric Proton Therapy Patients treated by Age Group age group (<1) Year, (1-4) Year, (5-9) Year, (10-14) Year, (15-18) Year in United States and its Forecast?
    •    What is the Pediatric Proton Therapy Market by Tumors (36 Types) in United States and its Forecast?
    •    How Many Pediatric Proton Therapy Patients treated by different Tumor Type in United States and its Forecast?
        What Type of Technology is being used at Proton Therapy Centers?


     

    1.    Research Findings

    2.    United States Pediatric Proton Therapy Market (Actual & Potential)
    2.1    United States Pediatric Proton Therapy Market & Forecast

    2.2    United States Potential Pediatric Proton Therapy Market & Forecast

    3.    USA Pediatric Proton Therapy Market by Age Group
    3.1    By Age Group (<1) Year

    3.2    By Age Group (1-4) Year

    3.3    By Age Group (5-9) Year

    3.4    By Age Group (10-14) Year

    3.5    By Age Group (15-18) Year

    4.    USA Pediatric Proton Therapy Patient Number - Actual and Potential
    4.1    USA Pediatric Patients Treated with Proton Therapy Actual Numbers & Forecast

    4.2    United States – Pediatric Patients with Proton Therapy Potential Numbers & Forecast

    5.    USA Pediatric Proton Therapy Patients Numbers by Age Group
    5.1    By Age (<1) Year

    5.2    By Age (1- 4) Year

    5.3    By Age (5- 9) Year

    5.4    By Age (10-14) Year

    5.5    By Age (15- 18) Year

    6.    Tumor Types – USA Pediatrics Proton Therapy Market (2010 – 2021)
    6.1    Glioma, Low Grade – Market & Forecast

    6.2    Glioma, High Grade – Market & Forecast

    6.3    Medulloblastoma – Market & Forecast

    6.4    Ependymoma – Market & Forecast

    6.5    ATRT – Market & Forecast

    6.6    Germinoma, Pure – Market & Forecast

    6.7    Germ Cell Tumor – Market & Forecast

    6.8    Craniopharyngioma – Market & Forecast

    6.9    PNET – Market & Forecast

    6.10    Pineoblastoma – Market & Forecast

    6.11    Chordoma/Chondrosarcoma – Market & Forecast

    6.12    Meningioma – Market & Forecast

    6.13    AVM – Market & Forecast

    6.14    Adenoma – Market & Forecast

    6.15    Choroid Plexus Carcinoma – Market & Forecast

    6.16    Retinoblastoma – Market & Forecast

    6.17    Osteosarcoma – Market & Forecast

    6.18    Ewing Sarcoma – Market & Forecast

    6.19    Rhabdomyosarcoma – Market & Forecast

    6.20    Other Sarcoma, High Grade – Market & Forecast

    6.21    Other Sarcoma, Low Grade – Market & Forecast

    6.22    Teratoma – Market & Forecast

    6.23    Neuroblastoma – Market & Forecast

    6.24    Ganglioglioma – Market & Forecast

    6.25    Wilm’s Tumor – Market & Forecast

    6.26    Carcinoma (non-CPC) – Market & Forecast

    6.27    Lymphoma, Hodgkin’s – Market & Forecast

    6.28    Lymphoma, Non-hodgkin’s – Market & Forecast

    6.29    Leukemia – Market & Forecast

    6.30    Desmoid – Market & Forecast

    6.31    Melanoma – Market & Forecast

    6.32    Pineal Parenchymal Tumor – Market & Forecast

    6.33    Esthesioneuroblastoma – Market & Forecast

    6.34    Angiofibroma – Market & Forecast

    6.35    Extrarenal Rhabdoid Tumor – Market & Forecast

    6.36    Others – Market & Forecast

    7.    Tumor Types – United States Pediatrics Proton Therapy Patients (2010 – 2021)
    7.1    Glioma, Low Grade – Patient Numbers & Forecast

    7.2    Glioma, High Grade - Patient Numbers & Forecast

    7.3    Medulloblastoma - Patient Numbers & Forecast

    7.4    Ependymoma - Patient Numbers & Forecast

    7.5    ATRT - Patient Numbers & Forecast

    7.6    Germinoma, pure - Patient Numbers & Forecast

    7.7    Germ Cell Tumor - Patient Numbers & Forecast

    7.8    Craniopharyngioma - Patient Numbers & Forecast

    7.9    PNET - Patient Numbers & Forecast

    7.10    Pineoblastoma - Patient Numbers & Forecast

    7.11    Chordoma/Chondrosarcoma - Patient Numbers & Forecast

    7.12    Meningioma - Patient Numbers & Forecast

    7.13    AVM - Patient Numbers & Forecast

    7.14    Adenoma - Patient Numbers & Forecast

    7.15    Choroid Plexus Carcinoma - Patient Numbers & Forecast

    7.16    Retinoblastoma - Patient Numbers & Forecast

    7.17    Osteosarcoma - Patient Numbers & Forecast

    7.18    Ewing Sarcoma - Patient Numbers & Forecast

    7.19    Rhabdomyosarcoma - Patient Numbers & Forecast

    7.20    Other Sarcoma, High Grade - Patient Numbers & Forecast

    7.21    Other Sarcoma, Low Grade - Patient Numbers & Forecast

    7.22    Teratoma - Patient Numbers & Forecast

    7.23    Neuroblastoma - Patient Numbers & Forecast

    7.24    Ganglioglioma - Patient Numbers & Forecast

    7.25    Wilm’s Tumor - Patient Numbers & Forecast

    7.26    Carcinoma (non-CPC) - Patient Numbers & Forecast

    7.27    Lymphoma, Hodgkin’s - Patient Numbers & Forecast

    7.28    Lymphoma, Non-hodgkin’s - Patient Numbers & Forecast

    7.29    Leukemia - Patient Numbers & Forecast

    7.30    Desmoid - Patient Numbers & Forecast

    7.31    Melanoma - Patient Numbers & Forecast

    7.32    Pineal Parenchymal Tumor - Patient Numbers & Forecast

    7.33    Esthesioneuroblastoma - Patient Numbers & Forecast

    7.34    Angiofibroma - Patient Numbers & Forecast

    7.35    Extrarenal Rhabdoid Tumor - Patient Numbers & Forecast

    7.36    Others - Patient Numbers & Forecast

    8.    Components of a Standard Proton Therapy Center
    8.1    Proton Accelerator
    8.1.1    Synchrotrons (example: LLUMC at Loma Linda)
    8.1.2    Cyclotrons (example: MGH Boston)
    8.1.3    Synchrocyclotrons (examples: Orsay, Uppsala)
    8.1.4    H-minus Synchrotrons
    8.1.5    Separated Sector Cyclotrons
    8.1.6    Super-conducting Cyclotrons
    8.1.7    Fast Cycling Synchrotron

    8.2    Beam Transport System

    8.3    Beam Delivery System
    8.3.1    The Passive Scattering Technique
    8.3.2    Beam Scanning

    8.4    Nozzle
    8.4.1    Single Scattering
    8.4.2    Double Scattering
    8.4.3    Uniform Scanning Nozzle
    8.4.4    Pencil Scanning Nozzle

    8.5    Treatment Planning System

    8.6    Image Viewers

    8.7    Patient Positioning System (PPS)

    8.8    Human Resource

    9.    Proton Therapy – Driving Factors
    9.1    Technology Advancement

    9.2    Rising Prevalence of Pediatric Cancer Patients in United States

    10.    Proton Therapy – Challenges
    10.1    Requires Huge Investment

    10.2    Operations Challenges

    11.    Global Proton Therapy - Company Analysis (2010-2021)
    11.1    IBA Proton Therapy
    11.1.1    Sales Analysis
    11.1.2    IBA List of Proton Therapy Centers

    11.2    Varian Medical Systems
    11.2.1    Sales Analysis

    11.3    Mitsubishi Electric Corporation
    11.3.1    Sales Analysis
    11.3.2    Mitsubishi List of Proton Therapy Center

    11.4    Hitachi
    11.4.1    Sales Analysis
    11.4.2    Hitachi List of Proton Therapy Center

    12.    Proton Therapy – Reimbursement Policies
    12.1    Proton Therapy Reimbursement Policies for Patients

    12.2    Proton Therapy Reimbursement for Institutions, Stakeholders and Manufacturers
     

    List of Figures

    Figure 2‑1: United States – Pediatric Proton Therapy Market (Million US$), 2010 – 2016
    Figure 2‑2: United States – Forecast for Pediatric Proton Therapy Market (Million US$), 2017 – 2021
    Figure 2‑3: United States – Potential Pediatric Proton Therapy Market (Million US$), 2010 – 2016
    Figure 2‑4: United States – Forecast for Potential Pediatric Proton Therapy Market (Million US$), 2017 – 2021

    Figure 3‑1: United States – Pediatric Proton Therapy Market by Age Group (<1) (Million US$), 2010 – 2016
    Figure 3‑2: United States – Forecast for Pediatric Proton Therapy Market by Age Group (<1) (Million US$), 2017 – 2021
    Figure 3‑3: United States – Pediatric Proton Therapy Market by Age Group (1-4) (Million US$), 2010 – 2016
    Figure 3‑4: United States – Forecast for Pediatric Proton Therapy Market by Age Group (1-4) (Million US$), 2017 – 2021
    Figure 3‑5: United States – Pediatric Proton Therapy Market by Age Group (5-9) (Million US$), 2010 – 2016
    Figure 3‑6: United States – Forecast for Pediatric Proton Therapy Market by Age Group (5-9) (Million US$), 2017 – 2021
    Figure 3‑7: United States – Pediatric Proton Therapy Market by Age Group (10-14) (Million US$), 2010 – 2016
    Figure 3‑8: United States – Forecast for Pediatric Proton Therapy Market by Age Group (10-14) (Million US$), 2017 – 2021
    Figure 3‑9: United States – Pediatric Proton Therapy Market by Age Group (15-18) (Million US$), 2010 – 2016
    Figure 3‑10: United States – Forecast for Pediatric Proton Therapy Market by Age Group (15-18) (Million US$), 2017 – 2021

    Figure 4‑1: United States – Pediatric Proton Therapy Patients (Number), 2010 – 2016
    Figure 4‑2: United States – Forecast for Pediatric Proton Therapy Patients (Number), 2017 – 2021
    Figure 4‑3: United States – Potential Pediatric Proton Therapy Patients (Number), 2010 – 2016
    Figure 4‑4: United States – Forecast for Potential Pediatric Proton Therapy Patients (Number), 2017 – 2021

    Figure 5‑1: United States – Pediatric Proton Therapy Patients by Age Group (<1) (Number), 2010 – 2016
    Figure 5‑2: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (<1) (Number), 2017 – 2021
    Figure 5‑3: United States – Pediatric Proton Therapy Patients by Age Group (1-4) (Number), 2010 – 2016
    Figure 5‑4: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (1-4) (Number), 2017 – 2021
    Figure 5‑5: United States – Pediatric Proton Therapy Patients by Age Group (5-9) (Number), 2010 – 2016
    Figure 5‑6: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (5-9) (Number), 2017 – 2021
    Figure 5‑7: United States – Pediatric Proton Therapy Patients by Age Group (10-14) (Number), 2010 – 2016
    Figure 5‑8: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (10-14) (Number), 2017 – 2021
    Figure 5‑9: United States – Pediatric Proton Therapy Patients by Age Group (15-18) (Number), 2010 – 2016
    Figure 5‑10: United States – Forecast for Pediatric Proton Therapy Patients by Age Group (15-18) (Number), 2017 – 2021

    Figure 6‑1: United States – Glioma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑2: United States – Forecast for Glioma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑3: United States – Glioma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑4: United States – Forecast for Glioma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑5: United States – Medulloblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑6: United States – Forecast for Medulloblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑7: United States – Ependymoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑8: United States – Forecast for Ependymoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑9: United States – ATRT Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑10: United States – Forecast for ATRT Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑11: United States – Germinoma, Pure Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑12: United States – Forecast for Germinoma, Pure Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑13: United States – Germ Cell Tumor Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑14: United States – Forecast for Germ Cell Tumor Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑15: United States – Craniopharyngioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑16: United States – Forecast for Craniopharyngioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑17: United States – PNET Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑18: United States – Forecast for PNET Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑19: United States – Pineoblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑20: United States – Forecast for Pineoblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑21: United States – Chordoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑22: United States – Forecast for Chordoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑23: United States – Meningioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑24: United States – Forecast for Meningioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑25: United States – AVM Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑26: United States – Forecast for AVM Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑27: United States – Adenoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑28: United States – Forecast for Adenoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑29: United States – Choroid Plexus Carcinoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑30: United States – Forecast for Choroid Plexus Carcinoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑31: United States – Retinoblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑32: United States – Forecast for Retinoblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑33: United States – Osteosarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑34: United States – Forecast for Osteosarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑35: United States – Ewing Sarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑36: United States – Forecast for Ewing sarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑37: United States – Rhabdomyosarcoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑38: United States – Forecast for Rhabdomyosarcoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑39: United States – Other Sarcoma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑40: United States – Forecast for Other Sarcoma, High Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑41: United States – Other Sarcoma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑42: United States – Forecast for Other Sarcoma, Low Grade Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑43: United States – Teratoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑44: United States – Forecast for Teratoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑45: United States – Neuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑46: United States – Forecast for Neuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑47: United States – Ganglioglioma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑48: United States – forecast for Ganglioglioma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑49: United States – Wilms tumor Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑50: United States – Forecast for Wilms tumor Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑51: United States – Carcinoma (non-CPC) Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑52: United States – Forecast for Carcinoma (non-CPC) Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑53: United States – Hodgkin's Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑54: United States – Forecast for Hodgkin's Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑55: United States – Non-Hodgkin Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑56: United States – Forecast for Non-Hodgkin Lymphoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑57: United States – Leukemia Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑58: United States – Forecast for Leukemia Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑59: United States – Desmoid Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑60: United States – Forecast for Desmoid Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑61: United States – Melanoma Pediatric Proton Therapy Market (Thousand US$), 2010 – 2016
    Figure 6‑62: United States – Forecast for Melanoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑63: United States – Pediatric Proton Therapy Market for Pineal Parenchymal Tumor (Thousand US$), 2010 – 2016
    Figure 6‑64: United States – Forecast for Pediatric Proton Therapy Market for Pineal Parenchymal Tumor (Thousand US$), 2017 – 2021
    Figure 6‑65: United States – Pediatric Proton Therapy Market for Esthesioneuroblastoma (Thousand US$), 2010 – 2016
    Figure 6‑66: United States – Forecast for Esthesioneuroblastoma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑67: United States – Pediatric Proton Therapy Market for Angiofibroma (Thousand US$), 2010 – 2016
    Figure 6‑68: United States – Forecast for Angiofibroma Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021
    Figure 6‑69: United States – Pediatric Proton Therapy Market for Extrarenal Rhabdoid Tumor (Thousand US$), 2010 – 2016
    Figure 6‑70: United States – Forecast for Pediatric Proton Therapy Market by Extrarenal Rhabdoid Tumor (Thousand US$), 2017 – 2021
    Figure 6‑71: United States – Pediatric Proton Therapy Market for Others (Thousand US$), 2010 – 2016
    Figure 6‑72: United States – Forecast for Others Pediatric Proton Therapy Market (Thousand US$), 2017 – 2021

    Figure 7‑1: United States – Pediatric Proton Therapy Patients by Glioma, Low Grade (Number), 2010 – 2016
    Figure 7‑2: United States – Forecast for Pediatric Proton Therapy Patients by Glioma, Low Grade (Number), 2017 – 2021
    Figure 7‑3: United States – Pediatric Proton Therapy Patients by Glioma, High Grade (Number), 2010 – 2016
    Figure 7‑4: United States – Forecast for Pediatric Proton Therapy Patients by Glioma, High Grade (Number), 2017 – 2021
    Figure 7‑5: United States – Pediatric Proton Therapy Patients by Medulloblastoma (Number), 2010 – 2016
    Figure 7‑6: United States – Forecast for Pediatric Proton Therapy Patients by Medulloblastoma (Number), 2017 – 2021
    Figure 7‑7: United States – Pediatric Proton Therapy Patients by Ependymoma (Number), 2010 – 2016
    Figure 7‑8: United States – Forecast for Pediatric Proton Therapy Patients by Ependymoma (Number), 2017 – 2021
    Figure 7‑9: United States – Pediatric Proton Therapy Patients by ATRT (Number), 2010 – 2016
    Figure 7‑10: United States – Forecast for Pediatric Proton Therapy Patients by ATRT (Number), 2017 – 2021
    Figure 7‑11: United States – Pediatric Proton Therapy Patients by Germinoma, pure (Number), 2010 – 2016
    Figure 7‑12: United States – Forecast for Pediatric Proton Therapy Patients by Germinoma, pure (Number), 2017 – 2021
    Figure 7‑13: United States – Pediatric Proton Therapy Patients by Germ Cell Tumor (Number), 2010 – 2016
    Figure 7‑14: United States – Forecast for Pediatric Proton Therapy Patients by Germ Cell Tumor (Number), 2017 – 2021
    Figure 7‑15: United States – Pediatric Proton Therapy Patients by Craniopharyngioma (Number), 2010 – 2016
    Figure 7‑16: United States – Forecast for Pediatric Proton Therapy Patients by Craniopharyngioma (Number), 2017 – 2021
    Figure 7‑17: United States – Pediatric Proton Therapy Patients by PNET (Number), 2010 – 2016
    Figure 7‑18: United States – Forecast for Pediatric Proton Therapy Patients by PNET (Number), 2017 – 2021
    Figure 7‑19: United States – Pediatric Proton Therapy Patients by Pineoblastoma (Number), 2010 – 2016
    Figure 7‑20: United States – Forecast for Pediatric Proton Therapy Patients by Pineoblastoma (Number), 2017 – 2021
    Figure 7‑21: United States – Pediatric Proton Therapy Patients by Chordoma/Chondrosarcoma (Number), 2010 – 2016
    Figure 7‑22: United States – Forecast for Pediatric Proton Therapy Patients by Chordoma/Chondrosarcoma (Number), 2017 – 2021
    Figure 7‑23: United States – Pediatric Proton Therapy Patients by Meningioma (Number), 2010 – 2016
    Figure 7‑24: United States – Forecast for Pediatric Proton Therapy Patients by Meningioma (Number), 2017 – 2021
    Figure 7‑25: United States – Pediatric Proton Therapy Patients by AVM (Number), 2010 – 2016
    Figure 7‑26: United States – Forecast for Pediatric Proton Therapy Patients by AVM (Number), 2017 – 2021
    Figure 7‑27: United States – Pediatric Proton Therapy Patients by Adenoma (Number), 2010 – 2016
    Figure 7‑28: United States – Forecast for Pediatric Proton Therapy Patients by Adenoma (Number), 2017 – 2021
    Figure 7‑29: United States – Pediatric Proton Therapy Patients by Choroid Plexus Carcinoma (Number), 2010 – 2016
    Figure 7‑30: United States – Forecast for Pediatric Proton Therapy Patients by Choroid Plexus Carcinoma (Number), 2017 – 2021
    Figure 7‑31: United States – Pediatric Proton Therapy Patients by Retinoblastoma (Number), 2010 – 2016
    Figure 7‑32: United States – Forecast for Pediatric Proton Therapy Patients by Retinoblastoma (Number), 2017 – 2021
    Figure 7‑33: United States – Pediatric Proton Therapy Patients by Osteosarcoma (Number), 2010 – 2016
    Figure 7‑34: United States – Forecast for Pediatric Proton Therapy Patients by Osteosarcoma (Number), 2017 – 2021
    Figure 7‑35: United States – Pediatric Proton Therapy Patients by Ewing Sarcoma (Number), 2010 – 2016
    Figure 7‑36: United States – Forecast for Pediatric Proton Therapy Patients by Ewing Sarcoma (Number), 2017 – 2021
    Figure 7‑37: United States – Pediatric Proton Therapy Patients by Rhabdomyosarcoma (Number), 2010 – 2016
    Figure 7‑38: United States – Forecast Pediatric Proton Therapy Patients by Rhabdomyosarcoma (Number), 2017 – 2021
    Figure 7‑39: United States – Pediatric Proton Therapy Patients by Other Sarcoma, High Grade (Number), 2010 – 2016
    Figure 7‑40: United States – Forecast for Pediatric Proton Therapy Patients by Other Sarcoma, High Grade (Number), 2017 – 2021
    Figure 7‑41: United States – Pediatric Proton Therapy Patients by Other Sarcoma, Low Grade (Number), 2010 – 2016
    Figure 7‑42: United States – Forecast for Pediatric Proton Therapy Patients by Other Sarcoma, Low Grade (Number), 2017 – 2021
    Figure 7‑43: United States – Pediatric Proton Therapy Patients by Teratoma (Number), 2010 – 2016
    Figure 7‑44: United States – Forecast for Pediatric Proton Therapy Patients by Teratoma (Number), 2017 – 2021
    Figure 7‑45: United States – Pediatric Proton Therapy Patients by Neuroblastoma (Number), 2010 – 2016
    Figure 7‑46: United States – Forecast for Pediatric Proton Therapy Patients by Neuroblastoma (Number), 2017 – 2021
    Figure 7‑47: United States – Pediatric Proton Therapy Patients by Ganglioglioma (Number), 2010 – 2016
    Figure 7‑48: United States – Forecast for Pediatric Proton Therapy Patients by Ganglioglioma (Number), 2017 – 2021
    Figure 7‑49: United States – Pediatric Proton Therapy Patients by Wilm’s Tumor (Number), 2010 – 2016
    Figure 7‑50: United States – Forecast for Pediatric Proton Therapy Patients by Wilm’s Tumor (Number), 2017 – 2021
    Figure 7‑51: United States – Pediatric Proton Therapy Patients by Carcinoma (non-CPC) (Number), 2010 – 2016
    Figure 7‑52: United States – Forecast for Pediatric Proton Therapy Patients by Carcinoma (non-CPC) (Number), 2017 – 2021
    Figure 7‑53: United States – Pediatric Proton Therapy Patients by Lymphoma, Hodgkin’s (Number), 2010 – 2016
    Figure 7‑54: United States – Forecast for Pediatric Proton Therapy Patients by Lymphoma, Hodgkin’s (Number), 2017 – 2021
    Figure 7‑55: United States – Pediatric Proton Therapy Patients by Lymphoma, Non-hodgkin’s (Number), 2010 – 2016
    Figure 7‑56: United States – Forecast for Pediatric Proton Therapy Patients by Lymphoma, Non-hodgkin’s (Number), 2010 – 2016
    Figure 7‑57: United States – Pediatric Proton Therapy Patients by Leukemia (Number), 2010 – 2016
    Figure 7‑58: United States – Forecast for Pediatric Proton Therapy Patients by Leukemia (Number), 2017 – 2021
    Figure 7‑59: United States – Pediatric Proton Therapy Patients by Desmoid (Number), 2010 – 2016
    Figure 7‑60: United States – Forecast for Pediatric Proton Therapy Patients by Desmoid (Number), 2017 – 2021
    Figure 7‑61: United States – Pediatric Proton Therapy Patients by Melanoma (Number), 2010 – 2016
    Figure 7‑62: United States – Forecast for Pediatric Proton Therapy Patients by Melanoma (Number), 2017 – 2021
    Figure 7‑63: United States – Pediatric Proton Therapy Patients by Pineal Parenchymal Tumor (Number), 2010 – 2016
    Figure 7‑64: United States – Forecast for Pediatric Proton Therapy Patients by Pineal Parenchymal Tumor (Number), 2017 – 2021
    Figure 7‑65: United States – Pediatric Proton Therapy Patients by Esthesioneuroblastoma (Number), 2010 – 2016
    Figure 7‑66: United States – Forecast for Pediatric Proton Therapy Patients by Esthesioneuroblastoma (Number), 2017 – 2021
    Figure 7‑67: United States – Pediatric Proton Therapy Patients by Angiofibroma (Number), 2010 – 2016
    Figure 7‑68: United States – Forecast for Pediatric Proton Therapy Patients by Angiofibroma (Number), 2017 – 2021
    Figure 7‑69: United States – Pediatric Proton Therapy Patients by Extrarenal Rhabdoid Tumor (Number), 2010 – 2016
    Figure 7‑70: United States – Forecast for Pediatric Proton Therapy Patients by Extrarenal Rhabdoid Tumor (Number), 2017 – 2021
    Figure 7‑71: United States – Pediatric Proton Therapy Patients by Others (Number), 2010 – 2016
    Figure 7‑72: United States – Forecast for Pediatric Proton Therapy Patients by Others (Number), 2017 – 2021

    Figure 9‑1: United States – Pediatric Patient Diagnosed With Cancer (Number), 2010 – 2016
    Figure 9‑2: United States – Forecast for Pediatric Patient Cancer Incidence (Number), 2017 – 2021

    Figure 11‑1: Global – IBA Proton Therapy Sales (Million US$), 2010 – 2016
    Figure 11‑2: Global – Forecast for IBA Proton Therapy Sales (Million US$), 2017 – 2021
    Figure 11‑3: Global – Varian Medical Systems Oncology Systems Sales (Million US$), 2010 – 2016
    Figure 11‑4: Global – Forecast for Varian Medical Systems Oncology Systems Sales (Million US$), 2017 – 2021
    Figure 11‑5: Global – Mitsubishi Electric Corporation Energy and Electric Systems Sales (Million US$), 2010 – 2016
    Figure 11‑6: Global – Forecast for Mitsubishi Electric Corporation Energy and Electric Systems Sales (Million US$), 2017 – 2021
    Figure 11‑7: Global – Hitachi Electronic Systems and Equipment Sales (Million US$), 2010 – 2016
    Figure 11‑8: Global – Forecast for Hitachi Electronic Systems and Equipment Sales (Million US$), 2017 – 2021

     

    List of Tables

    Table 11 1: Global – IBA Proton Therapy Centers in Operational and Under-Construction Phase    
    Table 11 2: Global – Mitsubishi Proton Therapy Centers in Operational and Under-Construction Phase    
    Table 11 3: Global – Hitachi Proton Therapy Centers in Operational and Under-Construction Phase    

     


    Related Products